

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Monday, August 14, 2017 2:28 PM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** Kite Pharma BLA CMC IR 08/14/2017

**Importance:** High

Dear Dr. Sproule,

We have the following request for CMC information:

1. Please submit available stability data for (b) (4) vector lots (b) (4) (described in Table 1 of Amendment #46). Please also provide a testing schedule for stability studies on these lots.
2. Please describe what method was used for cell viability testing on Patient lots (b) (4), described in Tables 5 and 6 of Amendment #46.
3. Please provide an electronic copy of label on the (b) (4) vector (b) (4).

**Please try to respond by August 18, 2017.**

Thanks

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax: 301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."